The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. METHODS: A randomised...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Rheum Dis
Autori principali: Boyle, D L, Soma, K, Hodge, J, Kavanaugh, A, Mandel, D, Mease, P, Shurmur, R, Singhal, A K, Wei, N, Rosengren, S, Kaplan, I, Krishnaswami, S, Luo, Z, Bradley, J, Firestein, G S
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2015
Soggetti:
Basic and Translational Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431345/
https://ncbi.nlm.nih.gov/pubmed/25398374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-206028
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi